Trius Therapeutics is a biopharmaceutical company focused
on the discovery, development and commercialization
of innovative antibiotics for serious, life-threatening infections

In The News

January 26, 2012

Trius Therapeutics, Inc. Prices Public Offering
of Common Stock

January 25, 2012

Trius Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

January 23, 2012

Trius Earns $5 Million Milestone Payment
from Bayer for Successful Completion
of First Phase 3 Trial of Tedizolid

Events & Publications

October, 2011

Genetic Environment and Stability
of cfr in MRSA CM05, Locke et al.

September, 2011

In Vitro Activity of Tedizolid (TR-700) Against Linezolid-Resistant Staphylococci, Rodriguez-Avial et al.